Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 18 of 18 entries
View as:

A Study in Healthy Volunteers to Investigate How Much Test Medicine [14C]-Uproleselan is Taken up by the Body When Administered Directly Into the Vein (IV)

Phase: N/A Priority: Normal
NCT ID: NCT03606447 Org: User:
Start: 08/14/18 End: 09/13/18 Due: 09/13/19

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

Phase: N/A Priority: Normal
NCT ID: NCT01119833 Org: User:
Start: 05/31/10 End: 12/31/13 Due: 12/31/14

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Phase: N/A Priority: Normal
NCT ID: NCT02433158 Org: User:
Start: 12/16/15 End: 11/15/19 Due: 11/15/20

A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.

Phase: N/A Priority: Normal
NCT ID: NCT02998099 Org: User:
Start: 01/31/17 End: 03/31/17 Due: 03/31/18

A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02813798 Org: User:
Start: 06/30/16 End: 02/28/18 Due: 02/28/19

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02217917 Org: User:
Start: 10/31/15 End: 04/30/16 Due: 04/30/17

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01941511 Org: User:
Start: 08/31/13 End: 08/31/14 Due: 08/31/15

A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02811822 Org: User:
Start: 06/30/16 End: 04/30/19 Due: 04/30/20

Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02168595 Org: User:
Start: 06/30/14 End: 04/30/15 Due: 04/30/16

Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

Phase: N/A Priority: Normal
NCT ID: NCT02744833 Org: User:
Start: 07/31/16 End: 11/30/16 Due: 11/30/17

Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03616470 Org: User:
Start: 10/15/18 End: 03/31/24 Due: 03/31/25

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

Phase: N/A Priority: Normal
NCT ID: NCT02306291 Org: User:
Start: 03/31/15 End: 05/31/18 Due: 05/31/19

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT02871570 Org: User:
Start: 09/30/16 End: 03/31/17 Due: 03/31/18

A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04197999 Org: User:
Start: 11/21/19 End: 08/25/21 Due: 08/25/22

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02931214 Org: User:
Start: 08/31/16 End: 11/30/18 Due: 11/30/19

A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02703051 Org: User:
Start: 11/30/15 End: 08/31/16 Due: 08/31/17

Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02271113 Org: User:
Start: 10/31/14 End: 03/31/16 Due: 03/31/17

Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

Phase: N/A Priority: Normal
NCT ID: NCT00911495 Org: User:
Start: 05/31/09 End: 09/30/10 Due: 09/30/11